​

Intellia Therapeutics Ownership | Who Owns Intellia Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Intellia Therapeutics Ownership Summary

Intellia Therapeutics is owned by 95.18% institutional investors, 4.80% insiders, and 0.02% retail investors. Ark investment management is the largest institutional shareholder, holding 11.49% of NTLA shares. ARK Disruptive Innovation Full Composite is the top mutual fund, with 8.11% of its assets in Intellia Therapeutics shares.

NTLA Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockIntellia Therapeutics95.18%4.80%0.02%
SectorHealthcare Stocks 492.67%11.09%-403.76%
IndustryBiotech Stocks 295.31%11.22%-206.53%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ark investment management11.92M11.49%$205.84B
Vanguard group11.04M10.65%$190.74M
Blackrock9.60M10.05%$214.79M
Blackrock funding, inc. /de9.28M8.94%$160.19M
Contrarius group5.89M5.68%$101.72M
State street4.36M4.57%$97.64M
Regeneron pharmaceuticals3.70M3.57%$63.95M
Baker bros. advisors lp2.68M2.58%$25.10M
Geode capital management2.59M2.50%$44.71M
Morgan stanley2.34M2.45%$52.32M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Regeneron pharmaceuticals3.70M9.13%$63.95M
Discovery value fund228.70K7.05%$3.95B
Contrarius group5.89M4.60%$101.72M
Contrarius investment management1.92M2.68%$42.87M
Ark investment management11.92M1.23%$205.84B
Orchard capital management81.60K1.22%$1.41M
Generali investments towarzystwo funduszy inwestycyjnych80.00K0.73%$1.38M
Iq eq fund management (ireland)494.47K0.58%$8.54M
Birchview capital, lp60.00K0.56%$562.80K
Himension capital (singapore) pte.729.42K0.53%$6.84M

Top Buyers

HolderShares% AssetsChange
Contrarius group5.89M4.60%4.34M
Baker bros. advisors lp2.68M0.24%2.03M
Ubs group1.74M0.00%1.46M
Jupiter asset management1.36M0.20%1.36M
Goldman sachs group2.03M0.00%1.00M

Top Sellers

HolderShares% AssetsChange
Deep track capital, lp---4.95M
Capital investors---3.78M
Casdin capital---2.00M
Alliancebernstein265.32K0.00%-1.93M
Pictet asset management sa---1.39M

New Positions

HolderShares% AssetsChangeValue
Jupiter asset management1.36M0.20%1.36M$23.52M
Graham capital management234.76K0.03%234.76K$2.20M
Avidity partners management lp232.00K0.43%232.00K$2.18M
Twinbeech capital lp137.76K0.03%137.76K$1.29M
Y-intercept (hong kong)137.29K0.06%137.29K$2.37M

Sold Out

HolderChange
Dinuzzo private wealth-1.00
Global financial private client-1.00
Activest wealth management-1.00
Richard w. paul & associates-2.00
Jfs wealth advisors-2.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 2025290-7.05%98,735,343-2.49%950.99%146-0.68%85-10.53%
Mar 31, 20256-98.05%3,804,135-96.17%30.04%3-98.41%1-98.55%
Dec 31, 2024286-2.39%92,252,291-1.01%911.07%17817.11%61-27.38%
Sep 30, 2024290-5.54%93,104,8603.35%921.07%150-7.41%84-4.55%
Jun 30, 20243020.67%90,028,919-0.69%941.05%1605.26%86-2.27%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
ARK Disruptive Innovation Full Composite8.71M8.11%966.00
ARK Innovation ETF8.28M7.71%61.21K
American Funds SMALLCAP World A3.78M3.65%3.78M
Vanguard US Total Market Shares ETF3.17M3.06%299.88K
Vanguard Total Stock Mkt Idx Inv3.17M2.95%-70.23K
ARK Genomic Revolution ETF2.89M2.69%-10.31K
ARK Genomic Revolution2.88M2.68%-220.20K
Vanguard Small Cap Index2.51M2.34%-16.78K
iShares Russell 2000 ETF2.48M2.31%-
Nikko AM ARK Disruptive Innovation A USD1.76M1.70%-68.46K

Recent Insider Transactions

DateNameRoleActivityValue
Oct 01, 2025Schultes Birgit C EVP, Chief Scientific OfficerSell$538.78
Oct 01, 2025Dube Michael P VP, Chief Accounting OfficerSell$32.52K
Aug 20, 2025CHASE WILLIAM J-Buy$1.00M
Jul 23, 2025Dulac Edward J III EVP, Chief Financial OfficerSell$104.62K
Jul 01, 2025Clark Eliana EVP, Chief Technical OfficerSell$10.04K

Insider Transactions Trends

DateBuySell
2025 Q4-2
2025 Q314
2025 Q2-2
2025 Q1-11
2024 Q4-1

NTLA Ownership FAQ

Who Owns Intellia Therapeutics?

Intellia Therapeutics shareholders are primarily institutional investors at 95.18%, followed by 4.80% insiders and 0.02% retail investors. The average institutional ownership in Intellia Therapeutics's industry, Biotech Stocks , is 295.31%, which Intellia Therapeutics falls below.

Who owns the most shares of Intellia Therapeutics?

Intellia Therapeutics’s largest shareholders are Ark investment management (11.92M shares, 11.49%), Vanguard group (11.04M shares, 10.65%), and Blackrock (9.6M shares, 10.05%). Together, they hold 32.19% of Intellia Therapeutics’s total shares outstanding.

Does Blackrock own Intellia Therapeutics?

Yes, BlackRock owns 10.05% of Intellia Therapeutics, totaling 9.6M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 214.79M$. In the last quarter, BlackRock increased its holdings by 488.34K shares, a 5.36% change.

Who is Intellia Therapeutics’s biggest shareholder by percentage of total assets invested?

Regeneron pharmaceuticals is Intellia Therapeutics’s biggest shareholder by percentage of total assets invested, with 9.13% of its assets in 3.7M Intellia Therapeutics shares, valued at 63.95M$.

Who is the top mutual fund holder of Intellia Therapeutics shares?

ARK Disruptive Innovation Full Composite is the top mutual fund holder of Intellia Therapeutics shares, with 8.11% of its total shares outstanding invested in 8.71M Intellia Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools